Targeting early events in T cell activation to construct improved vaccines

Molecular Immunology

Volumn 37, Issue 9, 2000, Pages 545-552

  Buchan, G S ^a   Young, S L ^a   Lockhart, E A ^a   Wales, J ^a   Faulkner, L ^a   Slobbe, L ^a   Baird, M A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antigen presentation; Cytokines; Dendritic cells; Liposomes; T cells; Vaccine; Virtual pathogen

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE; EPITOPE; LIVE VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNITY; IMMUNOREGULATION; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; DRUG ADMINISTRATION ROUTES; GENETIC VECTORS; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDES; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 0034546320     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(00)00073-0     Document Type: Article

References (65)

1. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition
2. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines
3. Liposomes as carriers for vaccines
4. Liposomes as carriers of antigens and adjuvants
5. Role of B-cell and Fc receptors in the selection of T-cell epitopes
6. A novel influenza subunit vaccine composed of liposomeencapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice
7. Dendritic cells and the control of immunity
8. Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus
9. Engineering of doubly antigenised immunoglobulins expressing T and B viral epitopes
10. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
11. Molecular organisation of histidine-tagged biomolecules at self-assembled lipid interfaces using a novel class of chelator lipids
12. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells
13. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite. P. falciparum
14. Interleukin 10 does not affect phagocytosis of particulate antigen by bone marrow derived dendritic cells, but does impair antigen presentation
15. Interleukin 2 linked to a peptide from influenza haemagglutinin enhances T cell activation by affecting the antigen presentation function of bone marrow derived dendritic cells
16. Immunological adjuvants: A role for liposomes
17. The immunological adjuvant and vaccine carrier properties of liposomes
18. Conjugation of interferongamma to antigen enhances its immunogenicity
19. Cytokines as immunological adjuvants
20. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation
21. Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs
22. Cytokine adjuvants: Lessons from the past-guidelines for the future?
23. The adjuvant potential of cytokines
24. Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV
25. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli
26. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing
27. Co-immunisation with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T cell immunity, but not protective efficacy against Mycobacterium tuberculosis
28. Antigen-specific cytotoxicity and cell number of adoptively transferred T cells are efficiently maintained in vivo by re-stimulation with an antigen/interleukin-2 fusion protein
29. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens
30. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production
31. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines
32. Protective humoral response against pneumococcal infection in mice elicited by recombinant BCG vaccines expressing pneumococcal surface protein A
33. Systemic and mucosal immunity induced by BCG vector expressing outer surface protein A of Borrelia burgdorferi
34. Receptor mediated antigen uptake and its effect on antigen presentation to class II restricted T lymphocytes
35. Antigenic presentation of small molecules and synthetic peptides conjugated to a preformed iscom carrier
36. In vivo administration of purified human interleukin 2. II. Half-life, immunological effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2
37. Chemically anambiguous peptide immunogen: Preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system
38. Use of a liposome delivery system to alter immune responses in vivo
39. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin
40. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies
41. Innate Immunity: Impact on the adaptive immune response
42. Relationships between structure and function in the Fc receptor family
43. Manipulation and potentiation of anti-mycobacterial immunity using recombinant BCG strains that secrete cytokines
44. Cytokines as potential vaccine adjuvants
45. Recombinant Mycobacterium bovis BCG secreting functional IL-2 enhances gamma interferon production by splenocytes
46. Biodegradable microparticles as controlled release antigen delivery systems
47. Immunity to mycobacteria
48. Recombinant interleukin 2 therapy in severe combined immunodeficiency disease
49. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
50. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly
51. Chemistry of peptides associated with MHC class I and class II molecules
52. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Down regulation by cytokines and bacterial products
53. An in vitro comparison of BCG and cytokine secreting BCG vaccines
54. Vaccination of the Leishmania major susceptible BALB/c mouse. I. The precise selection of peptide determinant influences CD4+ T cell subset expression
55. Receptor-mediated pinocytosis of manose glycoconjugates by macrophages: Characterisation and evidence for receptor recycling
56. New use of BCG for recombinant vaccines
57. The role of macrophages in the immunodominant action of liposomes: Effects of elimination of splenic macrophages on the immune response against intra venously injected liposome-associated albumin antigens
58. Idiotypic/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
59. Get into the groove! Targeting antigens to MHC class II
60. Immunoadjuvant action of liposomes: Mechanisms
61. Clinical cytotoxicity of cytokines used as haemopoietic growth factors
62. Enhanced Protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2
63. HPV6b virus like particles are potent immunogens without adjuvant in man